Organization and Nature of Business - Additional Information (Details) - USD ($)				3 Months Ended	9 Months Ended
	Aug. 18, 2022	Jul. 06, 2021	Aug. 25, 2020	Sep. 30, 2022	Sep. 30, 2022	Dec. 31, 2021
Organization and Nature of Business [Line Items]
Accumulated deficit				$ (348,925,000)	$ (348,925,000)	$ (228,982,000)
Cash, cash equivalents and marketable securities				595,600	595,600
Aggregate proceeds from issuance of private placement				$ 174,000	$ 174,000
Initial Public Offering
Organization and Nature of Business [Line Items]
Stock Issued During Period, Shares, New Issues			9,987,520
Common stock per share			$ 20.00
Gross proceeds from issuance initial public offering			$ 199,800,000
Private Placement | Vertex Pharmaceuticals Incorporated
Organization and Nature of Business [Line Items]
Stock Issued During Period, Shares, New Issues		49,928	676,354
Common stock per share		$ 47.00	$ 20.00
Aggregate proceeds from issuance of private placement		$ 2,300,000	$ 13,500,000
Underwriters
Organization and Nature of Business [Line Items]
Stock Issued During Period, Shares, New Issues		713,250	1,302,720
Follow-on Offering
Organization and Nature of Business [Line Items]
Net proceeds from sale of common stock in public offering		$ 257,000,000.0
Stock Issued During Period, Shares, New Issues		5,468,250
Common stock per share		$ 47.00
Private Investment in Public Equity "PIPE" [Member]
Organization and Nature of Business [Line Items]
Stock Issued During Period, Shares, New Issues	2,769,228
Common stock per share	$ 26.00
Pre-funded warrants to purchase	$ 3,000,000,000
Pre-funded warrant purchase price	$ 25.9999
Pre-funded warrants per share	$ 0.0001
Offering expenses	$ 149,800,000
Pre-funded warrants outstanding				3,000,000	3,000,000
Pre-funded warrants, exercised					$ 0
Increase or decrease pre-funded warrants, maximum	19.99%
Minimum pre-funded warrants, exercise	4.99%
Prior notice period, minimum	61 days